News AstraZeneca reveals $570m investment in Canada AstraZeneca has announced another major investment in Canada, tapping into the country's emergence as a "global hub" for clinical trials.
News Tris cues up filing for non-opioid pain drug on phase 3 win Tris Pharma has set its sights on an FDA filing for non-opioid pain drug cebranopadol this year after hitting the mark in an abdominoplasty trial.
R&D The future of precision psychiatry The mental health clinical trials market is expected to double to $4.27 billion in 2028, up from $2.15 billion in 2018, and
News High-dose semaglutide ramps up weight loss, says Novo Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.
News Boehringer drug for brain fog in schizophrenia fails trial Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.
R&D Partner Content Register Now for the AAPS National Biotechnology Conference The AAPS National Biotechnology Conference uncovers the trends driving today’s biotech markets.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
